Skip to content
RDL
Network
Ekosistem
Uygulama değiştir
EN
Hakkımızda
SSS
Giriş yap
Başla
Expression levels of interferon-ɣ and type 2 deiodinase in patients diagnosed with recurrent depressive disorders — Elżbieta Gałecka (2017) | RDL Network
Back
Cite
Save
Save for later
Share
Home
Publications
Expression levels of interferon-ɣ and type 2 deiodinase in patients diagnosed with recurrent depressive disorders
Shared by
Michael Maes
University of Electronic Science and Technology of China
Expression levels of interferon-ɣ and type 2 deiodinase in patients diagnosed with recurrent depressive disorders
Article
2017
en
Authors
+4 more
EG
Elżbieta Gałecka
MT
Monika Talarowska
Michael Maes
University Of Electronic Science & Technology Of China
Discussion
(0)
Sign in
to like and join the discussion.
No comments yet. Be the first to comment.
Related publications
Article
2017
Assessment of type 1 and type 3 deiodinase expression levels in depressive disorders
Elżbieta Gałecka
,
Anna Kumor‐Kisielewska
,
Agata Orzechowska
,
Michael Maes
,
Paweł Górski
,
Janusz Szemraj
Article
2013
Increased MicroRNA-146a Levels in Plasma of Patients with Newly Diagnosed Type 2 Diabetes Mellitus
Rong Ying
,
Wei Bao
,
Zhilei Shan
,
Jun Liu
,
Xuefeng Yu
,
Songfan Xia
,
Hui Gao
,
Xia Wang
,
Ping Yao
,
Frank B Hu
,
Liegang Liu
Article
2012
The expression of genes encoding for COX-2, MPO, iNOS, and sPLA2-IIA in patients with recurrent depressive disorder
Piotr Gałecki
,
Elżbieta Gałecka
,
Michael Maes
,
Marcelina Chamielec
,
Agata Orzechowska
,
Kinga Bobińska
,
Andrzej Lewiński
,
Janusz Szemraj
Article
2014
Inverse Association of Plasma Vanadium Levels with Newly Diagnosed Type 2 Diabetes in a Chinese Population
Xiaoyang Wang
,
Taoping Sun
,
Jing Yu Liu
,
Zhilei Shan
,
Yan Jin
,
Shihua Chen
,
Wei Bao
,
Frank B Hu
,
Li Liu
Article
2004
Lower activities of serum peptidases predict higher depressive and anxiety levels following interferon‐alpha‐based immunotherapy in patients with hepatitis C
Michael Maes
,
S. Bonaccorso
Discussion(0)
No comments yet. Be the first to comment.